Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
SK Biopharmaceuticals Co Ltd banner

SK Biopharmaceuticals Co Ltd
KRX:326030

Watchlist Manager
SK Biopharmaceuticals Co Ltd Logo
SK Biopharmaceuticals Co Ltd
KRX:326030
Watchlist
Price: 77 600 KRW -0.13% Market Closed
Market Cap: ₩6.1T
Write Note Create Alert Ask AI

Wall St Price Targets

Price Targets Summary
SK Biopharmaceuticals Co Ltd

Wall Street analysts forecast SK Biopharmaceuticals Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SK Biopharmaceuticals Co Ltd is 153 000 KRW with a low forecast of 74 740 KRW and a high forecast of 173 250 KRW.

Lowest Forecast
Wall Street Target
₩74 740
-4% Downside
Average Forecast
Wall Street Target
₩153 000
97% Upside
Highest Forecast
Wall Street Target
₩173 250
123% Upside
Lowest Forecast
Price Target
74 740 KRW
4% Downside
Average Forecast
Price Target
153 000 KRW
97% Upside
Highest Forecast
Price Target
173 250 KRW
123% Upside
SK Biopharmaceuticals Co Ltd Competitors:
Price Targets

Revenue
Forecast

152% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat
152% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat

Over the last 7 years, the compound annual growth rate for Revenue has been 152%. The projected CAGR for the next 5 years is 19%.

What are analyst estimates?

Gross Profit
Forecast

150% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
150% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

Over the last 7 years, the compound annual growth rate for Gross Profit has been 150%. The projected CAGR for the next 3 years is 26%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
30% / Year
Estimated Growth
Estimates Accuracy
10%
Average Beat
N/A
Past Growth
30% / Year
Estimated Growth
Estimates Accuracy
10%
Average Beat

The compound annual growth rate for Operating Income over the next 5 years is 30%.

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
58% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
N/A
Past Growth
58% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

The compound annual growth rate for Pre-Tax Income over the next 3 years is 58%.

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
25% / Year
Estimated Growth
Estimates Accuracy
17%
Average Beat
N/A
Past Growth
25% / Year
Estimated Growth
Estimates Accuracy
17%
Average Beat

The compound annual growth rate for Net Income over the next 3 years is 25%.

What are analyst estimates?

Continue Research

Summary
intrinsic value, competitors valuation, and company profile.
DCF Valuation
stock valuation using Discount Cash Flow valuation method.
Relative Valuation
stock valuation using valuation multiples.
Wall St Estimates
price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is SK Biopharmaceuticals Co Ltd's stock price target?
Price Target
153 000 KRW

According to Wall Street analysts, the average 1-year price target for SK Biopharmaceuticals Co Ltd is 153 000 KRW with a low forecast of 74 740 KRW and a high forecast of 173 250 KRW.

What is the Revenue forecast for SK Biopharmaceuticals Co Ltd?
Projected CAGR
19%

Over the last 7 years, the compound annual growth rate for Revenue has been 152%. The projected CAGR for the next 5 years is 19%.

What is the Gross Profit forecast for SK Biopharmaceuticals Co Ltd?
Projected CAGR
26%

Over the last 7 years, the compound annual growth rate for Gross Profit has been 150%. The projected CAGR for the next 3 years is 26%.

What is the Operating Income forecast for SK Biopharmaceuticals Co Ltd?
Projected CAGR
30%

The compound annual growth rate for Operating Income over the next 5 years is 30%.

What is the Pre-Tax Income forecast for SK Biopharmaceuticals Co Ltd?
Projected CAGR
58%

The compound annual growth rate for Pre-Tax Income over the next 3 years is 58%.

What is the Net Income forecast for SK Biopharmaceuticals Co Ltd?
Projected CAGR
25%

The compound annual growth rate for Net Income over the next 3 years is 25%.

Back to Top
ALPHA SPREAD
Follow us
Join 358,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.